Have you or someone you know been diagnosed with persistent or chronic ITP?

• A study evaluating the safety of oral Rilazbrutinib in adolescents and adults with ITP.

Study Benefits

• This medication has been seen to reduce the destruction of platelets and also reduce the impairment of platelet production
• First oral medication of its kind to treat refractory or relapsed ITP

Study Volunteers Must Meet the Following Criteria

• Males and females
• Ages 18 and above with ITP of greater than 3 months in duration
• Aages 12-18 with ITP of greater than 6 months in duration

Study Participant Expectations

• 60-week study duration
• 12 to 14 weeks of blinded study treatment
• 28 weeks of open label medication administration
• 4 weeks of post-dose follow up
• 12-month long term extension study available

Cost

• There is no cost to participate.
• Patients who qualify may be compensated for time and travel